Endotoxin content in neonatal formulas, fortification, and lactoferrin products: association with outcomes and guidance on acceptable limits.
Endotoxin content in neonatal formulas, fortification, and lactoferrin products: association with outcomes and guidance on acceptable limits.
复制标题
DOI:
10.1007/s10534-022-00487-1
复制
发表时间:
2023-06
期刊:
影响因子:
3.5
通讯作者:
Jensen, David
中科院分区:
文献类型:
--
作者:
Kaufman, David A.;Perks, Patti H.;Greenberg, Rachel G.;Jensen, David
While endotoxin (lipopolysaccharide) can be harmful and contribute to morbidity and mortality with Gram-negative sepsis or necrotizing enterocolitis in preterm infants, non-toxic amounts are produced as part of the neonatal microbiome and may be present in enteral nutrition and medications administered. The United States Food and Drug Administration has given guidance for endotoxin concentration limits for intravenous medications and fluids of 5 endotoxin units/kg/hour (120 endotoxin units/kg/day), but no guidance for amounts of endotoxin in enteral products. To determine baseline exposure to infants in the neonatal intensive care unit, we examined endotoxin content of enteral formulas and fortification used for preterm infants, as well as bovine lactoferrin products. We also examined endotoxin exposure and outcomes in very low birth weight infants. Endotoxin content was measured using kinetic chromogenic limulus amebocyte lysate analysis. Daily endotoxin exposure from enteral formulas ranged between < 75 to 7110 endotoxin units/kg and from lactoferrin products from 7 to 3720 endotoxin units/kg. In examining neonatal outcomes from a bovine lactoferrin product studied at three different escalating doses (100, 200, and 300 mg/kg/day), we measured endotoxin in the lactoferrin product and daily exposure was 1089 (N = 10), 2178 (N = 10) and 3287 (N = 11) endotoxin units/kg, respectively. There were no cases of necrotizing enterocolitis or mortality and no lactoferrin-related adverse effects in these patients. Enteral endotoxin daily exposures from lactoferrin products are similar to amounts in preterm enteral nutrition and appear safe and not associated with patient harm. Testing enteral products and establishing safety limits may improve care of high risk patients. The online version contains supplementary material available at 10.1007/s10534-022-00487-1.
登录
查看更多内容
影响因子:
5.3
作者:
Townsend, Stacy;Barron, Juncal Caubilla;Forsythe, Stephen
通讯作者:
Forsythe, Stephen
影响因子:
5.9
作者:
Sochaczewska D;Ziętek M;Dołęgowska B;Kordek A;Szczuko M
通讯作者:
Szczuko M
DOI:
10.1164/rccm.200810-1533oc
发表时间:
2009-03-01
影响因子:
24.7
作者:
Smit, Lidwien A. M.;Siroux, Valerie;Kauffmann, Francine
通讯作者:
Kauffmann, Francine
影响因子:
3.5
作者:
VANSLOOTEN, JC;BHUVANASVARI, TV;STANLEY, J
通讯作者:
STANLEY, J
DOI:
10.1007/s10024-002-0602-z
发表时间:
2003-01
期刊:
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
影响因子:
--
作者:
Hsueh W;Caplan MS;Qu XW;Tan XD;De Plaen IG;Gonzalez-Crussi F
通讯作者:
Gonzalez-Crussi F